FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation

Phase 2

Completed

Conditions: Malignant Neoplasm

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Atorvastatin Calcium
Procedure: Peripheral Blood Stem Cell Transplantation

First Posted Date: 2012-02-03

Last Posted Date: 2017-08-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 83

Registration Number: NCT01525407

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Stanford University Hospitals and Clinics, Stanford, California, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States

Improving Smoking Cessation Quitlines: Pilot Study of Acceptance Therapy

Not Applicable

Completed

Conditions: Smoking

Interventions: Behavioral: Acceptance Therapy (ACT)
Other: Cognitive Behavioral Therapy (CBT)

First Posted Date: 2012-02-03

Last Posted Date: 2014-05-26

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 121

Registration Number: NCT01525420

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD)

Phase 1

Completed

Conditions: Graft-Versus-Host Disease (GVHD) Acute on Chronic

Interventions: Drug: Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]

First Posted Date: 2012-02-01

Last Posted Date: 2018-10-30

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT01523821

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclosporine
Drug: Fludarabine Phosphate
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Radiation: Total-Body Irradiation
Radiation: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8

First Posted Date: 2012-01-02

Last Posted Date: 2019-12-09

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 15

Registration Number: NCT01503242

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Vitamin D and Adipose Tissue Inflammation

Not Applicable

Completed

Conditions: Vitamin D Deficiency
Obesity
Intestinal Permeability
Type 2 Diabetes Mellitus

Interventions: Dietary Supplement: Vitamin D3

First Posted Date: 2011-11-22

Last Posted Date: 2014-04-04

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 18

Registration Number: NCT01477034

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery

Phase 1

Completed

Conditions: Stage IV Adult Soft Tissue Sarcoma
Adult Liposarcoma
Adult Synovial Sarcoma
Recurrent Adult Soft Tissue Sarcoma
Stage III Adult Soft Tissue Sarcoma

Interventions: Drug: cyclophosphamide
Biological: NY-ESO-1-specific T cells
Other: laboratory biomarker analysis

First Posted Date: 2011-11-22

Last Posted Date: 2014-12-11

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 6

Registration Number: NCT01477021

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant

Phase 1

Completed

Conditions: Refractory Chronic Lymphocytic Leukemia
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Immunoblastic Large Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia
Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia

Interventions: Biological: allogeneic cytomegalovirus-specific cytotoxic T lymphocytes

First Posted Date: 2011-11-21

Last Posted Date: 2017-02-15

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 1

Registration Number: NCT01475058

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission

Phase 2

Terminated

Conditions: Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Adult Acute Promyelocytic Leukemia (M3)
Adult Erythroleukemia (M6a)
Secondary Acute Myeloid Leukemia
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)

Interventions: Drug: bortezomib

First Posted Date: 2011-11-04

Last Posted Date: 2017-04-04

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 6

Registration Number: NCT01465386

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Phase 2

Terminated

Conditions: Post-Transplant Lymphoproliferative Disorder
Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Burkitt Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
Refractory Burkitt Lymphoma

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclosporine
Drug: Fludarabine Phosphate
Radiation: Indium In-111 Ibritumomab Tiuxetan
Drug: Mycophenolate Mofetil
Other: Pharmacological Study
Biological: Rituximab
Radiation: Total-Body Irradiation
Radiation: Yttrium Y-90 Ibritumomab Tiuxetan
Drug: Fludarabine

First Posted Date: 2011-09-15

Last Posted Date: 2021-07-20

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT01434472

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies

Phase 2

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Myeloid Leukemia in Remission
Adult Erythroleukemia (M6a)
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Adult Pure Erythroid Leukemia (M6b)
Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Blastic Phase Chronic Myelogenous Leukemia

Interventions: Drug: cyclophosphamide
Drug: cyclosporine
Procedure: peripheral blood stem cell transplantation
Radiation: total-body irradiation
Drug: fludarabine phosphate
Drug: busulfan
Procedure: allogeneic hematopoietic stem cell transplantation

First Posted Date: 2011-09-02

Last Posted Date: 2017-05-19

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 43

Registration Number: NCT01427881

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Home Terms & Conditions Privacy Policy